Cargando…
Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept
BACKGROUND: Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. A clinical trial of 22 patients with moderate to severe psoriasis treated with alefacept was conducte...
Autores principales: | Suárez-Fariñas, Mayte, Shah, Kejal R, Haider, Asifa S, Krueger, James G, Lowes, Michelle A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831811/ https://www.ncbi.nlm.nih.gov/pubmed/20152045 http://dx.doi.org/10.1186/1471-5945-10-1 |
Ejemplares similares
-
Evaluation of the Psoriasis Transcriptome across Different Studies by Gene Set Enrichment Analysis (GSEA)
por: Suárez-Fariñas, Mayte, et al.
Publicado: (2010) -
The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
por: Jenneck, Claudia, et al.
Publicado: (2007) -
Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015) -
Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease
por: Tian, Suyan, et al.
Publicado: (2012) -
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis
por: Chamian, Francesca, et al.
Publicado: (2007)